Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 2
1988 2
1989 1
1990 2
1992 1
1993 2
1994 1
1995 4
1996 5
1997 1
1998 2
1999 3
2000 5
2001 5
2002 2
2003 3
2004 2
2005 2
2006 9
2007 8
2008 17
2009 15
2010 5
2011 7
2012 4
2013 11
2014 9
2015 7
2016 2
2017 3
2018 3
2019 4
2020 2
2021 4
2022 1
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean t haerle[Author] (30 results)?
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Fernandez RA, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Haertle L, et al. Clin Cancer Res. 2023 Jan 4;29(1):279-288. doi: 10.1158/1078-0432.CCR-22-1161. Clin Cancer Res. 2023. PMID: 36282272
All-trans retinoic acid works synergistically with the gamma-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
García-Guerrero E, Rodríguez-Lobato LG, Sierro-Martínez B, Danhof S, Bates S, Frenz S, Haertle L, Götz R, Sauer M, Rasche L, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M, Prommersberger SR. García-Guerrero E, et al. Among authors: haertle l. Haematologica. 2023 Feb 1;108(2):568-580. doi: 10.3324/haematol.2022.281339. Haematologica. 2023. PMID: 36722406 Free PMC article.
Accordingly, there is a desire to augment and sustain BCMA expression on MM cells in patients that receive BCMA-CAR T-cell therapy. We used all-trans retinoic acid (ATRA) to augment BCMA expression on MM cells and to increase the efficacy of BCMA-CAR T cells in pre- …
Accordingly, there is a desire to augment and sustain BCMA expression on MM cells in patients that receive BCMA-CAR T-cell therapy. W …
Mapping of HCG-receptor complexes.
Remy JJ, Couture L, Pantel J, Haertlé T, Rabesona H, Bozon V, Pajot-Augy E, Robert P, Troalen F, Salesse R, Bidart JM. Remy JJ, et al. Among authors: haertle t. Mol Cell Endocrinol. 1996 Dec 20;125(1-2):79-91. doi: 10.1016/s0303-7207(96)03955-x. Mol Cell Endocrinol. 1996. PMID: 9027346 Review.
Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Fernández RA, Bittrich M, Ruiz-Heredia Y, Da Viá M, Zovko J, Garitano-Trojaola A, Bolli N, Ruckdeschel A, Stühmer T, Chatterjee M, Kull M, Krönke J, Agirre X, Martin-Subero JI, Raab P, Einsele H, Rasche L, Martinez-Lopez J, Haaf T, Kortüm KM. Haertle L, et al. Blood. 2021 Nov 4;138(18):1721-1726. doi: 10.1182/blood.2020010452. Blood. 2021. PMID: 34115836 Free PMC article.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X, Besse A, Peter J, Steinhardt MJ, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Lopez MM, Munawar U, Riedel A, Han S, Maurits E, Overkleeft HS, Florea B, Einsele H, Kortüm KM, Driessen C, Besse L, Rasche L. Zhou X, et al. Among authors: haertle l. Haematologica. 2023 Jun 1;108(6):1628-1639. doi: 10.3324/haematol.2022.282225. Haematologica. 2023. PMID: 36727403 Free PMC article.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kortüm KM, Rasche L. Zhou X, et al. Among authors: haertle l. Br J Haematol. 2024 May 8. doi: 10.1111/bjh.19515. Online ahead of print. Br J Haematol. 2024. PMID: 38719214

Low baseline haemoglobin (Hb) and PLT were associated with long-lasting grade 3 anaemia (r = -0.56, p < 0.001) and thrombocytopenia (r = -0.44, p = 0.002) respectively. We observed dynamics of CAR-negative T-cell subsets following CAR T-cell infusion. In the late

…

Low baseline haemoglobin (Hb) and PLT were associated with long-lasting grade 3 anaemia (r = -0.56, p < 0.001) and thrombocytopenia (r =

…
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.
Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt MJ, Truger M, Mersi J, Teufel E, Han S, Haertle L, Banholzer N, Eiring P, Danhof S, Navarro-Aguadero MA, Fernandez-Martin A, Ortiz-Ruiz A, Barrio S, Gallardo M, Valeri A, Castellano E, Raab P, Rudert M, Haferlach C, Sauer M, Hudecek M, Martinez-Lopez J, Waldschmidt J, Einsele H, Rasche L, Kortüm KM. Munawar U, et al. Among authors: haertle l. Commun Biol. 2023 Dec 21;6(1):1299. doi: 10.1038/s42003-023-05683-4. Commun Biol. 2023. PMID: 38129580 Free PMC article.
The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms, resulting in improved response …
The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugate …
152 results